Peer-reviewed veterinary case report
Simvastatin lowers drug resistance in canine mammary cancer cells
By Cruz, P et al.·Published in Polish journal of veterinary sciences·2018·Department of Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Simvastatin modulates β-catenin/MDR1 expression on spheres derived from CF41.Mg canine mammary carcinoma cells.
- Species:
- dog
Plain-English summary
A study looked at how simvastatin, a cholesterol-lowering medication, affects cancer cells in dogs with mammary tumors. It found that simvastatin can help make these cancer cells more sensitive to chemotherapy by reducing the levels of a protein called MDR1, which often makes cancer cells resistant to treatment. This means that using simvastatin alongside traditional cancer treatments could potentially improve outcomes for dogs with mammary tumors. While this research is promising, it's important for pet owners to discuss treatment options with their veterinarian.
People also search for: dog mammary tumor treatment · simvastatin for dogs cancer · canine cancer chemotherapy options
Abstract
The presence of cancer stem-like cells (CSC) within canine mammary tumors, may explain partly local recurrence and spreading, since their ability to resist conventional antitumor treatments as chemo and radiotherapy. It has been recently described that simvastatin - a drug that inhibits synthesis of cholesterol - attenuates the proliferation of canine mammary CSC derived from CF41.Mg canine mammary carcinoma cells, promoting their chemosensitizing and apoptosis. The canonical Wnt/β-catenin pathway is usually activated at CSC and up-regulates multidrug resistance protein 1 (MDR1), triggering chemoresistance. In the present study, we analyze the effect of simvastatin on β-catenin/MDR1 expression in spheres obtained from the CF41.Mg cell line as a model of CSC. Simvastatin increased phosphorylation of β-catenin without affecting its total expression. Moreover, MDR1 expression was decreased by simvastatin. These results suggest that simvastatin would facilitate the degradation of β-catenin, decreasing MDR1 expression and contributing to the chemosensitizing effects of the statin on canine mammary CSC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29624022/